MCLA-129 is under clinical development by Merus and currently in Phase II for Paranasal Sinus And Nasal Cavity Cancer. According to GlobalData, Phase II drugs for Paranasal Sinus And Nasal Cavity Cancer does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the MCLA-129 LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

MCLA-129 overview

MCLA-129 is under development for the treatment of solid tumor including non-small cell lung cancer, gastric cancer, esophageal squamous cell cancer (ESCC), gastroesophageal junction (GC/GEJ) adenocarcinoma, Paranasal Sinus And Nasal Cavity Cancer; Oropharyngeal Cancer; Laryngeal Cancer, head and neck cancer and colorectal cancer. It is administered through intravenous drip. The therapeutic candidate is a bi-specific monoclonal antibody that acts by targeting epidermal growth factor receptor (EGFR) and hepatocyte growth factor receptor (MET). The drug candidate is being developed based on Biclonics platform.

Merus overview

Merus is a pharmaceutical company that discovers and develops antibody therapeutics for cancer indications. The company is investigating MCLA-128, for the treatment of metastatic breast cancer and solid tumors; ONO-4685, for the treatment of autoimmune disease. It is also evaluating MCLA-158 and MCLA-129, to treat solid tumors and MCLA-145, a T-cell agonist targeting hematological malignancy and solid tumors. Merus utilizes Multiclonics, Biclonics and Triclonics technology platforms for developing antibodies to treat cancer. The company works in collaboration with Incyte Corporation, Simcere Pharmaceutical Group, Ono Pharmaceutical Co., Ltd. and Betta Pharmaceuticals Co Ltd. Merus is headquartered in Utrecht, the Netherlands.

For a complete picture of MCLA-129’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 7 February 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.